Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2018-12-17
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of tofacitinib modified release
formulation (11mg QD) versus tofacitinib modified release formulation plus continued
methotrexate treatment in subjects with moderate to severe rheumatoid arthritis who are
insufficiently responding to their stable dose of methotrexate treatment.